Clusters of tumor cells are often observed in the blood of cancer patients. These structures have been described as malignant entities for more than 50 years, although their comprehensive characterization is lacking. Contrary to current consensus, we demonstrate that a discrete population of circulating cell clusters isolated from the blood of colorectal cancer patients are not cancerous but consist of tumor-derived endothelial cells. These clusters express both epithelial and mesenchymal markers, consistent with previous reports on circulating tumor cell (CTC) phenotyping. However, unlike CTCs, they do not mirror the genetic variations of matched tumors. Transcriptomic analysis of single clusters revealed that these structures exhibit an endothelial phenotype and can be traced back to the tumor endothelium. Further results show that tumor-derived endothelial clusters do not form by coagulation or by outgrowth of single circulating endothelial cells, supporting a direct release of clusters from the tumor vasculature. The isolation and enumeration of these benign clusters distinguished healthy volunteers from treatment-naïve as well as pathological early-stage (≤IIA) colorectal cancer patients with high accuracy, suggesting that tumor-derived circulating endothelial cell clusters could be used as a means of noninvasive screening for colorectal cancer. In contrast to CTCs, tumorderived endothelial cell clusters may also provide important information about the underlying tumor vasculature at the time of diagnosis, during treatment, and throughout the course of the disease.
INTRODUCTION
Circulating tumor cells (CTCs) comprise a rare population of cells often found in the blood of cancer patients. They continue to undergo extensive characterization with the hopes that they will offer insights into cancer metastasis and also provide better biomarkers of disease progression and therapeutic response (1) . Enumeration of CTCs has revealed prognostic information for metastatic breast cancer, colorectal cancer (CRC), and prostate cancer patients (2) , whereas the data supporting CTC burden for the prediction of treatment effectiveness are less established (3, 4) . The molecular profile of CTCs, rather than their quantity, might be a better approach for predicting drug responses (5) .
In addition to their recognition as individual cells, CTCs have been observed as clusters of multiple cells since at least 1960 (6) . Such clusters expressed mesenchymal markers in a longitudinal study of metastatic breast cancer patients (7), particularly FOXC1, which was a marker of epithelial-to-mesenchymal transition (EMT) (7, 8) . Recently, CTC clusters in blood from both breast and prostate cancer patients correlated with shorter progression-free survival (9) . Aceto et al. (9) further studied the formation and dynamics of CTC clusters in preclinical models, demonstrating a causative role for CTC clusters in breast cancer progression. A prospective trial in lung cancer patients confirmed that CTC clusters [also called circulating tumor microemboli (CTM)] were less apoptotic than single CTCs, and their detection was associated with poorer overall and progression-free survival (10) .
Despite the high interest associated with these cells, their characterization has been relatively limited, owing to technical challenges of isolation and single-cell analysis. The clinical relevance of CTC clusters is not well defined, especially compared with that of single CTCs. To overcome these limitations, we comprehensively studied CTC clusters at the single-cell scale from a cohort of unselected CRC patients, by integrating microfiltration techniques, high-throughput DNA sequencing and RNA sequencing (RNA-seq), and computational modeling applied to clinical specimens. In CRC patients, CTC clusters were not malignant but were instead tumor-derived endothelial cells (tECs) correlating with features of the underlying tumor vasculature. Notably, the isolation and count of these clusters could distinguish healthy volunteers from preoperative, early-stage (≤IIA) CRC patients with high accuracy, indicating a potential role for circulating tEC clusters as a screening biomarker for CRC.
RESULTS

Isolation and retrieval of single CD45
− clusters using a silicon-based microfiltration device We originally aimed to analyze the transcriptional and genetic profiles of single CTCs in CRC patients and so developed a label-free microfiltration device, which isolated cells on the basis of size (11) (12) (13) and enabled both retrieval and downstream analysis of CTCs (Fig. 1 , A to C, and fig. S1A ). From the device, 98% of the captured cells could be retrieved for downstream molecular analysis (fig. S1B). We optimized CTC enrichment and retrieval efficiency by spiking 1 ml of donor blood with 30 SW620 cells, a CRC cell line with a median diameter similar to CTCs (~12 mm) (14) (fig. S1C ). We obtained an optimal trade-off between retrieval efficiency and cell purity using a flow rate of 0.25 ml/min and microsieve pore sizes of 9 to 10 mm (Fig. 1D ). This resulted in >90% SW620 retrieval efficiency with >5000-fold depletion of white blood cells, which are considered impurities (fig. S1D). Similar retrieval efficiencies were obtained using three alternative CRC cell lines of varying sizes (fig. S1, C and E).
We next filtered CTCs from a series of five CRC patients and stained the isolated cells for epithelial cell adhesion molecule (EpCAM), a canonical CTC marker, and CD45, a marker for white blood cells. We did not detect EpCAM + cells (Fig. 1 , E and F); however, we noted the presence of large (average diameter,~40 mm) clusters of EpCAM
− cells (Fig. 1, F to H). The isolated clusters had a cytomorphology consistent with malignancy, such as atypical nuclei, prominent nucleoli, and high nuclear-tocytoplasmic ratio (Fig. 1H ).
The CD45
− clusters express keratins and mesenchymal markers but do not mirror primary tumor mutations CTCs have been shown to lose EpCAM expression in circulation, suggesting a drift from the epithelial phenotype (7, 8, 15) . Because of their malignant cytomorphology and loss of EpCAM expression, which might indicate ongoing EMT of tumor cells (7), we hypothesized that these CD45 − clusters harbored genetic alterations mirroring those occurring in the primary tumor. To identify DNA mutations in single cells or clusters undergoing EMT, we developed a polymerase chain reaction (PCR)-based method to simultaneously quantify RNA transcripts and detect DNA mutations, which is called single-cell RNA and mutational analysis PCR (scrmPCR) (fig . S2  and table S1 ). scrmPCR was first tested on known mutant alleles in an epithelial-like (DLD-1) and a mesenchymal-like (RKO) CRC cell line. The efficiency of targeted DNA amplification was about 70% for single cells and >90% for at least three cells for each amplicon ( fig. S2 ). Eight clusters derived from four patients had mostly mesenchymal markers, including FN1, SERPINE1, and FOXC1, but three of the clusters also expressed the epithelial marker KRT8 (Fig. 2, A and B) . EMT marker profiles in the clusters were confirmed by staining for pan-cytokeratin (panCK) and vimentin ( fig. S3A) .
We sequenced the same single clusters for mutations present in the corresponding primary tumors because mutations matching the primary tumor are often found in CTCs (16) . Surprisingly, all tested DNA sequence hotspots matched the wild-type alleles (Fig. 2C) . We further applied targeted high-throughput DNA sequencing to eight commonly mutated genes in DNA amplified from 15 single CTC clusters (n = 6 patients) and their corresponding primary tumor tissues. To avoid false-positive mutations introduced by the amplification procedure, we only considered mutations with >10% variant allele frequency (VAF) (table S2). In agreement with the scrmPCR results, mutations found in the tumor tissues were not detected in the CD45 − clusters (table S3) . Similarly, mutations found in the clusters were not detected in the tumor tissues (table S4 and fig. S3 , B and C). However, we detected multiple matching germline variants using the same method (0 of 58 matching mutations versus 12 of 28 matching germline variants; P = 2 × 10 −7 , power = 0.997, two-tailed Fisher's exact test) (table S5). We next performed array comparative genomic hybridization (aCGH) to detect chromosomal abnormalities using amplified DNA from 12 single clusters (n = 4 patients) because copy number variations for CTCs from lung cancer patients have been shown to mirror those of primary tumor tissue (18) . However, unlike matched primary tumors, our clusters had normal cytogenetic profiles ( In summary, although analysis of individual CTC clusters revealed cytomorphologies and epithelial-mesenchymal marker expression similar to those of a previous report on CTCs (7) , 100% (27 of 27) of single CD45
− clusters from nine patients did not share the genetic anomalies found in matching primary tumor tissues. In addition, DNA sequencing of 15 single CD45 − clusters from six patients revealed the presence of mutations that were not found in the tumor tissue (table S3 and fig. S4 ). These observations suggest that the source of the CD45 − clusters is not the tumor epithelium. − clusters, we found that all transcriptomes were associated with cell types of the endothelial lineage (Fig. 3A) . We confirmed this result by scrmPCR in an additional 14 clusters from four patients (Fig.  3B) . These results are in agreement with our findings from Fig. 2 because endothelial cells are known to express both mesenchymal markers and various keratins (classical epithelial markers) (19) . Without exception, all clusters, including those displaying a malignant cytomorphology, stained for endothelial markers such as CD31, VWF, and CD144 (Fig. 3C ) but were negative for CD45 or markers of megakaryocytic lineages such as CD41 and CD42B. Thus, in our CRC patients, all circulating CTC clusters were of endothelial origin. In addition, we did not detect single tumor cells within our clusters.
Our findings are in line with those of El-Heliebi et al. (20) , reporting CD31 expression on circulating nonhematological cells (CNHCs) from kidney cancer patients, but are not consistent with a recent report describing CTC clusters of malignant origins (9) . Cell-type inference based on the single-cell scale RNA-seq data for CTC clusters in the study of Aceto et al. (9) indicated, in contrast to our data, the presence of epithelial-derived cells ( fig. S7 ). Further experiments indicated that our circulating endothelial cell clusters were negative for CD133, an established marker for endothelial progenitor cells (EPCs) (Fig. 3D ) (21) . In addition, an EPC clonogenic assay (22) revealed that the endothelial clusters did not contain EPCs because live clusters failed to proliferate on a fibronectin substrate over a 30-day period (Fig. 3E) . Therefore, the cellular structures characterized in our study represent a distinct population of nonproliferating endothelial cell clusters circulating in the blood of CRC patients (table S11).
Circulating endothelial clusters are tumor-derived Principal component analysis (PCA) revealed a stronger association of the endothelial cell cluster transcriptomes with the tumor tissues than with the normal tissue samples ( fig. S8A ), indicating that the clusters might be tECs. To test this hypothesis, we isolated normal endothelial cells (nECs) and tECs from matched frozen tissue samples and profiled them by RNAseq ( fig. S8B and table S7 ). We also profiled the RNA expression of three primary endothelial cell types derived from the umbilical vein, normal skin, and prostate (HUVECs, HDMECs, and HPrMEC, respectively). The average expression of the endothelial cell cluster genes associated significantly with the intestinal-derived endothelial cells, but not with other nECs (fig.  S8C ). We subsequently classified the endothelial cell clusters on the basis of differential gene expression derived by comparing nEC with tEC transcriptomes ( fig. S8D ). Using a linear discriminant analysis (LDA) model derived from this comparison, we could classify 16 of 18 endothelial cell clusters as tECs and the remaining 2 clusters as nECs (Fig. 4A ). This enrichment was significantly different from random classification and indicated that most circulating endothelial cell clusters belonged to the population of tECs.
If the endothelial cell clusters originated from the tumor vasculature, we would expect a drop of cluster count shortly after tumor resection. 
Colon endoth. To test this hypothesis, we collected paired samples from 17 CRC patients 0 to 24 hours before and 24 to 72 hours after surgical tumor resection (n = 34 samples in total). Tumor removal caused a sharp, significant decline in the numbers of circulating endothelial cell clusters, supporting the hypothesis that these structures were tumor-derived ( Fig. 4B and table S12 ). In addition, this experiment indicates that circulating endothelial cell clusters do not originate from the peripheral circulation as outgrowth of single circulating endothelial cells but instead might be directly released as clusters from the tumor vasculature.
Folate hydrolase (FOLH1), the gene coding for prostate-specific membrane antigen (PSMA), is specifically expressed in the tumor vasculature of various cancer types but is absent in normal vasculature and peripheral blood (23, 24) . FOLH1 expression was detected in CD31 + CD45 − cells isolated from fresh CRC tissues and in microfiltrates from the blood of 7 of 11 CRC patients, but not in endothelial cells isolated from normal tissues or in microfiltrates derived from healthy donors (Fig. 4C) , providing further support for the tumor origin of our endothelial cell clusters. In addition, RNA-seq on the single circulating endothelial cell clusters indicated the expression of several published tumor endothelial markers ( fig. S8E) (23, 25) .
Using a CRC xenograft mouse model, we tested whether clusters of tECs were released in the circulation by transplanting tumors harboring fluorescent stroma into normal, wild-type mice and then analyzing the presence of single and multinucleated fluorescent endothelial cells in the blood by flow cytometry (fig. S9 , A to D). Circulating, multinucleated green fluorescent protein (GFP)-positive endothelial cells were present in three of four mice with transplanted GFP + xenografts but not in the control group ( fig. S9E ), indicating that tEC clusters were in the circulation of mice with growing tumors.
Finally, we investigated whether the number of circulating endothelial clusters correlated with features of the underlying tumor vasculature in CRC patients by analyzing blood vessels in tumor tissues isolated from patients with a low (≤10 per 2 ml of blood) or high (>10 per 2 ml of blood) endothelial cluster count. Although the median number of microvessel units did not differ between patients, the median number of lumens and their sizes were significantly higher in patients with high numbers of circulating endothelial cell clusters (Fig. 4, D and E) . In addition, we noted an increase of mosaic and damaged vessels in tumor tissues compared to matched normal tissues and in patients with high endothelial cluster counts compared to patients with low cluster counts (Fig. 4, F than being shed as a cluster from the tumor. However, the circulating endothelial clusters that we isolated from CRC patients stained negative for fibrin, the main component of the coagulation cascade (Fig. 5A) , and did not contain platelets (Fig. 3C and table S11 ). In addition, in CRC patients, the number of endothelial clusters did not correlate with the concentration of plasma D dimer, a marker for intravascular coagulation (Fig. 5B) .
To test whether circulating endothelial cells coagulate to form clusters in circulation, we injected fluorescently labeled single (dissociated) murine colorectal tumor (CT26)-derived endothelial cells into the tail vein of Balb/c mice and analyzed the formation of multinucleated events at different time points after injection (Fig. 5, C to E) . Single endothelial cells did not aggregate to form multicolored clusters and were cleared within 60 min upon injection (Fig. 5F ). These experiments provide additional support for the hypothesis that tEC clusters circulating in the blood of CRC patients may be directly shed from the tumor vasculature.
Tumor-derived endothelial cell clusters are prevalent in CRC patients
The associations between circulating endothelial cell clusters and the primary tumor prompted us to investigate whether these clusters were indicators of CRC. We counted endothelial cell clusters from a test set composed of 141 clinical specimens taken from 125 subjects (45 control healthy volunteers and a consecutive series of 80 CRC patients, including the above-mentioned patients) (table S13). At least one cluster was detected in 76.2% (61 of 80) of CRC patients, compared to only 2.2% (1 of 45) of healthy individuals (Fig. 6A ). Treatment-naïve CRC patients (n = 52) presented significantly higher endothelial cluster counts than patients who had already received any treatment for CRC (n = 28) (Fig. 6B) . However, endothelial cell cluster count was not associated with clinical parameters such as tumor stage, grade, or presence of distant metastasis (Fig. 6B and fig. S10A ).
Analysis of endothelial cell cluster distributions over time indicated that surgical resection of the primary tumor had the strongest effect on cluster counts (Fig. 6C and table S14), confirming the results in Fig. 4B that show a sharp decline in the numbers of circulating endothelial cell clusters before and after surgical resection of the tumor and providing further support for the association of circulating endothelial cell clusters with the presence of a primary tumor. The presence of these cells in 86.5% of treatment-naïve patients (45 of 52) but only in 2.2% of healthy controls (1 of 45) indicated that the endothelial cell cluster count might be useful in assisting CRC diagnosis. Treatment-naïve patients were distinguished from healthy controls on the basis of their endothelial cell cluster burden [area under the curve (AUC), 0.930] (Fig. 6D ). CRC patients with early-stage pathological tumors (stage ≤IIA) were also positive for endothelial cell clusters in 86.4% of cases (19 of 22) , with an AUC of 0.922 (Fig. 6D) . A second independent set of 100 samples (17 treatment-naïve CRC S10, B and C) . Together, the widespread presence of circulating endothelial cell clusters in treatment-naïve patients, but not in healthy individuals, indicates the potential usefulness of endothelial cell cluster count as a diagnostic adjunct for CRC, even early in disease (stage ≤IIA).
DISCUSSION
Here, we present a subpopulation of tumor-derived cells of endothelial origin that appear to challenge the consensus that all CTC clusters are malignant entities. Intending to isolate CTCs from CRC patients, we instead identified clusters with both epithelial and mesenchymal characteristics that expressed endothelial markers. Through a series of biochemical, genetic, and in vivo analyses, we determined that these cells are nonmalignant, are tumor-derived, are of endothelial origin, and reflect the properties of the primary tumor vasculature. Our study provides experimental evidence for the occurrence of a second tumorderived cellular entity in the blood, alongside bona fide CTCs. In support of our findings, a recent study described a subpopulation of CD276 + mature circulating endothelial cells, correlating with the presence of a primary tumor in esophageal and non-small cell lung cancer patients (26) . Tumor-derived endothelial cell clusters might be senescent or nonreplicative endothelial cells shed as multiple-cell structures from the chaotic tumor vasculature as it undergoes pathological angiogenesis (27) , a recognized early event in CRC tumor progression (28) . It is not clear how large clusters of cells travel from the primary tumor to the peripheral blood vasculature. One of the possible routes to bypass the capillary circuit could be through arteriovenous anastomoses, which are large circulatory connections between arterial and venous circulation (29) . Recently, Au et al. (30) showed that clusters of tumor cells, owing to their high deformability, can even traverse capillarysized blood vessels.
Unlike Aceto et al. (9), we did not detect the presence of clusters of epithelial CTCs. This might be the result of different patient profiles. Aceto et al. (9) analyzed blood samples from terminal breast cancer patients, whereas our patients were mostly preoperative CRC patients. A second explanation may be that epithelial clusters are more deformable than endothelial clusters and consequently traversed the microsieve pores of our device during the isolation procedure (30) . Nonetheless, we can conclude that CTC clusters do not constitute a homogeneous population and that at least two different tumor-derived population exist: an epithelial-derived population, characterized by malignant potential, and the endothelial population described in this study. Although the endothelial cluster cytomorphology is reminiscent of malignancy, with expression of keratins and mesenchymal markers, these cells should not be confused with malignant CTCs undergoing EMT. Research efforts interrogating the role of EMT in CTC clusters should consider the spurious relationships introduced by unintentional isolation of circulating endothelial cell clusters. For example, our endothelial clusters not only expressed vimentin but also were positive for mesenchymal genetic markers such as FN1, SERPINE1, and FOXC1. A few circulating endothelial clusters expressed transcripts for keratin 8 and 18 or stained positive for the pan-keratin antibody C11, further suggesting a potential confounding role of tECs in CTC studies, especially those using labelfree isolation techniques (17) .
Our study has some limitations. For example, we could not study the number of single tECs in circulation because our device would not fully recover cells with a diameter of <10 mm. In addition, we could not determine whether mutations found in our endothelial clusters were technical artifacts, owing to the whole-genome amplification procedure (which are known to occur especially in PCR-based amplifications), or real sporadic mutations (table S4) . The presence of potentially false-positive mutations in our samples, however, does not compromise our results ultimately because only matching mutations between circulating clusters and tumor tissue would be conclusive. Finally, we note that aberrant endothelial clusters similar to the ones we have characterized here have been reported in patients with increased risk for acute myocardial infarction (31) . This indicates that the presence of endothelial clusters in the blood might not be specific to neoplastic diseases, but rather a general indicator for vascular fragility.
In conclusion, we describe circulating endothelial cell clusters as a tumor-derived entity widespread in all stages of CRC. This insight opens up multiple new opportunities for translational research in querying disease status, in CRC and other cancers. For example, endothelial cluster burden may be used for early CRC detection. Additional prospective trials, including patients with colorectal adenomas, would be required to validate such diagnostic utility. Profiling of circulating endothelial cell clusters also promises to reveal features of the underlying tumor vasculature, particularly on a dynamic basis. For example, drug responses to antiangiogenic drugs could be tested using endothelial cluster counts. These cells may also be characterized to select patients who would respond to drugs targeting endothelial surface markers currently under clinical evaluation, such as PSMA (24) . In addition, live circulating endothelial clusters could offer an intriguing in vitro model to test drug responses targeting the tumor vasculature.
MATERIALS AND METHODS
Study design
The aim of this study was to comprehensively characterize CTCs in unselected CRC patients as a noninvasive method to derive information on underlying tumor characteristics. Devices and methods were optimized using cell lines and healthy donor blood samples before the study of clinical samples. Initial observations of the presence of circulating CD45 − clusters were recorded from a pilot series of five patients. Further molecular characterization studies were performed on circulating CD45
− clusters in unselected patients as described in table S14. Concurrently, we designed a case-control study to determine whether CD45 − clusters counts were associated with the presence of CRC. To determine the required minimal sample size, we first assumed that there was no association between samples positive for CD45
− clusters (≥1 cluster per 2 ml of blood) and CRC (null hypothesis). For a target power of 0.95, this resulted in an estimated minimal sample size of n = 72 using the pwr.chisq.test function of the pwr package in the R environment (version 3.1.0) (32) . An effect size of w = 0.5 was assumed at the two-sided significance level of 0.01. The effect size w was chosen on the basis of the pilot test of five CRC patients (all positive for circulating CD45 − clusters) (Fig. 1D ) and information derived from four healthy controls with negative cluster counts. Moreover, we 
Device fabrication
Silicon microsieves were fabricated as described by Lim et al. (13) . The microsieve consisted of a silicon disk with an overall diameter (ø) of 7.3 mm and a 300-mm-thick support ring. The central capture region measured ø = 5.3 mm and was 60 mm thick; it contained 100,000 circular pores obtained by deep reactive ion etching. To embed the microsieve in a sterile 3-ml syringe, we designed an acrylic sleeve insert consisting of an inlet channel with ø = 8.58 mm tapering to a ø = 5.54-mm channel, which corresponded to the microsieve cell capture region. The sleeve insert housed the microsieve and silicone O-rings (0.5 mm thick) that ensured a good seal and provided cushioning, as shown in Fig. 1B . Details on device assembly and microfiltration optimization are provided in the Supplementary Materials and Methods.
On-sieve immunofluorescence Cell suspensions were stained for 30 min directly "on-sieve" after five washes in phosphate-buffered saline containing 0.5% bovine serum albumin, 2 mM EDTA, and human FcR Blocking Reagent (Miltenyi Biotec) using the antibodies and fluorescent dyes listed in the Supplementary Materials and Methods. After a washing step, cells were retrieved and visualized in suspension under an inverted fluorescence microscope (IX81, Olympus) for imaging, counting, and/or micromanipulation. Images were recorded using MetaMorph software (Molecular Devices) with a CoolSNAP HQ2 CCD camera (Photometrics).
Circulating CD45
− clusters definition and count Circulating CD45
− clusters were defined in this study as "any CD45 − cell or CD45 − cellular cluster with a major axis of >10 mm and having at least two clearly distinct nuclei." All identified clusters stained positive for endothelial markers CD31, CD144, or VWF (Fig. 3C) . Therefore, in our study, CD45
− clusters and endothelial cell clusters refer to the same population. Cellular populations belonging to the megakaryocytic lineages, with large lobulated single nuclei or large round single nuclei, were excluded from the analysis. The characteristic cytomorphology of these cells was clearly different from that of CD45 − clusters with positive staining for CD41 and CD42B. Megakaryocytic cells were predominantly observed in CRC patients undergoing treatment. Single endothelial cells were also excluded from the analysis. CD45 − clusters were counted by transferring the microfiltrate obtained from 2 ml of whole blood to the well of a 96-well plate. After brief centrifugation, the cell clusters were identified and counted by manually scanning the target well three times using a 20× objective. A positive sample was defined by the detection of at least one CD45
− cluster.
Single-cell RNA and mutational analysis PCR All primers were designed using Primer-BLAST (33) . For each RNA transcript, primers were designed either to span exon-exon boundaries or to anneal to regions separated by at least one intron on the corresponding genomic DNA region. Primers for mutational analysis were designed to bind intronic regions of the target gene (table S1 ). The scrmPCR method is highlighted in fig. S2A and integrated several workflow steps derived from the CellsDirect One-Step qRT-PCR Kit (Invitrogen), the Biomark HD system (Fluidigm), and the work of Peixoto et al. (34) . Further details are provided in the Supplementary Materials and Methods.
Targeted resequencing and aCGH of circulating CD45 − clusters Single CD45
− clusters (n = 34 from 12 patients) were subjected to whole-genome amplification using the GenomePlex Single Cell Whole Genome Amplification Kit (Sigma) according to the manufacturer's instructions. This method was chosen after comparison tests for efficiency of amplification with an alternative method based on multiple displacement amplification. For the aCGH experiment, 50 pg of tissue DNA samples was amplified using the same procedure. All amplified samples were tested for ACTB DNA amplification by quantitative PCR. Nine clusters were removed from the analysis because of poor amplification of the reference gene. For targeted resequencing, a custom gene panel was designed to target exons for NRAS, CTNNB1, PIK3CA, EGFR, BRAF, PTEN, KRAS, AKT1, and TP53 genes (~6.1 kb). The libraries were constructed using Ion AmpliSeq Library Kits 2.0 (Life Technologies) with 10 ng of input DNA from the amplified clusters or the unamplified tissue DNA. Fifteen libraries were successfully generated from an initial number of 25 single CD45 − clusters. The targeted resequencing run was performed using an Ion Torrent Personal Genome Machine Sequencer (Life Technologies). Variants were called using the Ion Torrent Variant Caller Plugin with high-stringency settings. aCGH was performed by hybridizing 250 ng of DNA to CytoScan 750K arrays (Affymetrix) according to the manufacturer's instructions and using recommended reagents. Data were analyzed and visualized using ChAS software version 2.1 (Affymetrix).
cDNA synthesis and RNA-seq cDNA was synthesized from 30 single CD45 − clusters, 10 pg of whole tissue, 10 pg of laser-dissected endothelial cells, or 10 pg of primary endothelial cell RNA. To this end, we used the SMARTer Ultra Low RNA Kit (Clontech Laboratories) and long-distance PCR for 25 cycles for the clusters and 18 cycles for the remaining samples. At this stage, four clusters were excluded from the analysis because of non-amplification. For each sample, cDNA was sheared using the Adaptive Focused Acoustics system (Covaris). Libraries were constructed using the NEBNext DNA Library Prep Master Mix Kit (New England Biolabs). Eight clusters were further removed from the analysis because of poor library quality. All remaining libraries were barcoded using unique indices and pooled for RNA-seq run on an Illumina HiSeq 2000 platform. Data were mapped to human genome version 19 (hg19) using TopHat (version 2). Cufflinks (version 2.2) was used to quantify fragments per kilobase of transcript per million mapped reads (FPKM) (35) .
RNA-seq data analysis
The cell-type inference workflow was implemented in a custom R script (available upon request). PCA, differential gene expression analysis, and LDA were performed in the R environment (version 3.1.0) (32) . Further details are in the Supplementary Materials and Methods.
Microvessel staining and analysis Immunohistochemical staining of CD31 was performed on all available formalin-fixed and paraffin-embedded tissues (n = 28) with matching CD45 − cluster count. Tissue sections (4 mm) were placed on poly-L-lysine slides and stained with anti-CD31 antibodies in a 1:50 dilution (JC70A, Dako) for 20 min following the manufacturer's instructions on a BOND Automated Stainer (Leica Biosystems). Microvessel density and lumen counts on all sections were determined similarly as described previously (36) . See the Supplementary Materials and Methods for more details.
Experimental mice
All animals were housed at the Biological Resource Centre, Agency for Science, Technology and Research (A*STAR). Animal procedures were approved by the Institutional Animal Care and Use Committee of A*STAR and performed in compliance with the National Advisory Committee for Laboratory Animal Research (NACLAR) Guidelines. Experimental procedures are described in Fig. 5C and fig. S9A , with details provided in the Supplementary Materials and Methods.
Statistical analyses
All statistical analyses were performed in the R environment (version 3.1.0) (32) . Unpaired samples were tested using a two-tailed WilcoxonMann-Whitney U test with Bonferroni correction in the case of multiple comparisons. For paired samples, the two-tailed Wilcoxon signed-rank test was used. For each test, the exact P value was computed using the coin package. ROC curves with AUC and 95% CI were computed using the pROC package. Hierarchical clustering with bootstrapped P values in fig. S8C was computed using pvclust. To simplify the interpretation and comparison of effect size, the effect size r was derived for each statistical test as follows: r ¼ jZj = ffiffiffi n p , where Z is the z score calculated from the Wilcoxon-Mann-Whitney U or the Wilcoxon signed-rank test. r was converted from the resulting AUC and odds ratio as described in (37) . Using Cohen's definition, r = 0.1 can be interpreted as a small effect, r = 0.3 can be interpreted as a medium effect, and r = 0.5 can be interpreted as a large effect (37) . Box plots were drawn with boxes representing the IQR, a line across the box indicating the median, and whiskers indicating 1.5 × IQR. Outliers were not shown. Correlations were described using Kendall's tau (t) coefficient and its derived P value. The significance threshold was set at 0.05.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/8/345/345ra89/DC1 Materials and Methods Fig. S1 . Device setup, retrieval efficiency, and sample output purity. Table S1 . scrmPCR primers used in this study. Table S2 . Whole genome amplification (WGA) false-positives are detected only at VAF < 10%. Table S3 . Circulating CD45 − clusters do not mirror matching primary tumor mutations. Table S4 . Sporadic mutations in circulating CD45 − clusters are not detected in matching primary tumor tissues. Table S5 . Germline variants in tumor tissues and circulating CD45 − cell clusters (coverage and zygosity). Table S6 . RNA-seq data: number of uniquely mapped reads to hg19 exons. Table S7 . RNA-seq data: processed data (FPKM) of all samples described in the study. Table S8 . Definition of the cell types used for the inference algorithm. Table S9 . Top 80 genes ordered from highest to lowest specificity index (S) for each cell type selected for the inference algorithm. Table S10 . Positive published RNA-seq control samples used to validate the inference algorithm. Table S11 . Characteristics of tEC clusters isolated in this study. Table S12 . Circulating endothelial cell cluster count before and after surgery. Table S13 . Baseline patients' and healthy donors' characteristics. Table S14 . CD45 − cluster count for each baseline sample type and number of single clusters analyzed for each technique in the corresponding samples.
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